Indian generics makers on a roll

Indian generics makers are on a roll. Yesterday, a Ranbaxy-Ipca Laboratories unit got the OK to make generic Metformin; today, a Sun Pharmaceuticals subsidiary won a tentative FDA for its version of Prandin, a type 2 diabetes drug originally made by Novo Nordisk.

Caraco Pharmaceutical Laboratories, based in Detroit, says it's first out of the chute with generic repaglinide, and it's hoping for 180-day marketing exclusivity. The approval is contingent on Caraco's resolution of any patent issues with Novo Nordisk, now under litigation.

• read the report from the Detroit Free Press

Related Articles: Patent 'cliff' looms for Big Pharma. Report Indian court spurns Novartis on patent challenge. Report Generic competition slashes prices. Report India's biotech future is bright. Report